BIOGEN INC (BIIB)

Noteworthy Thursday Option Activity: BIIB, ADM, TMUS

RBC starts Lexeo at outperform, cites Friedreich's ataxia drug opportunity (NASDAQ:LXEO)

RBC Capital Markets has initiated coverage of Lexeo Therapeutics (LXEO) with an outperform rating, citing the company’s management team and commercial opportuni

Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Interesting BIIB Put And Call Options For July 2024

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biotech companies are edging closer to finding the answers behind Alzheimer's disease.

Ionis says Angelman syndrome drug well tolerated in study (NASDAQ:IONS)

Ionis Pharmaceuticals shared positive clinical update for investigational drug ION582 in Angelman syndrome trial.

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review

The major indexes ended long win streaks. Datadog led earnings winners.

The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?

The real competitive battle is about to begin, and it will last a long time.

Biogen (BIIB) Q3 2023 Earnings Call Transcript

BIIB earnings call for the period ending September 30, 2023.

Biogen stock gains as company posts Q3 growth (NASDAQ:BIIB)

Biogen (BIIB) shares rise as the company reports its first quarterly revenue growth in three years following the acquisition of Reata Pharmaceuticals. Read more here.

Biogen Non-GAAP EPS of $4.36 beats by $0.37, revenue of $2.53B beats by $130M (NASDAQ:BIIB)

Biogen's Q3 Non-GAAP EPS of $4.36 beats expectations by $0.37, while revenue of $2.53B exceeds estimates by $130M.

Biogen Lowers 2023 Earnings Guidance on Costs of Reata Purchase

Biogen Inc. lowered its full-year earnings guidance on acquisition-related costs and predicted a smaller dip in sales after quarterly revenue beat analysts’ expectations.

Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount

The company shares in the profits and sales related to Alzheimer's treatment, Leqembi.

Noteworthy Tuesday Option Activity: CVX, NXPI, BIIB

3 Biotech Moonshots to Bet on the Future of Health

Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.

Biogen Appoints Monish Patolawala to its Board of Directors

Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation

Biogen Becomes Oversold (BIIB)

EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON

INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED...

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment

Both companies are working on under-the-skin injections for Alzheimer's treatment.

Prothena stock falls on Biogen's new Alzheimer’s drug

Prothena (PRTA) and BioVie (BIVI) stocks decline after Biogen (BIIB) and Eisai (ESAIY) reported positive data for their new Alzheimer's injectable. Read more here.

December 8th Options Now Available For Biogen (BIIB)

Biogen says new Leqembi formulation better than IV version (NASDAQ:BIIB)

Biogen's new subcutaneous formulation of Alzheimer's therapy Leqembi shows better efficacy and fewer side effects compared to the intravenous version. Read morew here.

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients...

EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON

INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED...